Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

NCT03459391 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Acute Respiratory Infection

Interventions

DRUG: XC221 60 mg
DRUG: XC221 200 mg
DRUG: Placebo

Sponsor

PHARMENTERPRISES LLC